바이오모아 (BioMoa) — ADC · Antibody

9268프로그램 35FDA 승인

0오늘 방문

738누적 방문

8122갱신 대기 S–CData Tier S/A/B차세대 1068HER2 breast 5456Antibody 2744CGT →Psoriasis →NSCLC 35FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

Anti-Thyroglobulin mTCR PBL (Anti-Thyroglobulin mTCR PBL)

Metastatic Thyroid Cancer · Metastatic Thyroid Cancer

#MetastaticThyroidCancer#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 DISCONTINUED

ADCBiologicstaleJiangsu Alphamab Biopharmaceuti…Phase 2

JSKN033 (JSKN033)

Cervical Cancer · Cervical Cancer

#CervicalCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

ADCBiologicstaleFudan UniversityPhase 2

Observational Cohort (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (Observational Cohort))

Bladder Cancer; Metastatic Urothelial Carcinoma · Bladder Cancer

#BladderCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 RECRUITING

CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes (autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes)

Skin Cancer; Melanoma · Skin Cancer

#SkinCancer#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 DISCONTINUED

AntibodystaleChia Tai Tianqing Pharmaceutica…Phase 2

TQB2922 injection+TAS-102 tablets ± Bevacizumab (TQB2922 injection+TAS-102 tablets ± Bevacizumab)

RAS/BRAF Wild Type Colorectal Cancer · RAS/BRAF Wild Type Colorectal Cancer

#RASBRAFWildTypeColorectalCancer#Antibody#Phase2#항체#면역항체+4

임상시험 1상태 RECRUITING

CGTBiologicstaleInge Marie SvanePhase 1

ADP-TILIL7 (ADP-TILIL7)

Melanoma Stage III; Melanoma Stage IV · Melanoma Stage III

#MelanomaStageIII#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

AntibodystaleAmgenPhase 2

EGFR inhibitors (panitumumab, panitumumab (EGFR inhibitors))

Recurrence Free Survival · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3

효능 ORR 19%임상시험 1상태 RECRUITING

ADCBiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan + FLO)

Esophagogastric Adenocarcinoma · Esophagogastric Adenocarcinoma

#EsophagogastricAdenocarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

ADCBiologicstaleHummingbird BiosciencePhase 2

ENV-501 (ENV-501)

Melanoma (Skin); Non Small Cell Lung Cancer · Melanoma (Skin)

#MelanomaSkin#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 RECRUITING

AntibodystaleRochePhase 1

JS001+Bevacizumab (JS001+Bevacizumab)

Advanced Malignant Solid Tumors · Advanced Malignant Solid Tumors

#AdvancedMalignantSolidTumors#Antibody#Phase1#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleRochePhase 3

Capecitabine plus bevacizumab (Capecitabine plus bevacizumab)

Elderly Patients; Metastatic Colorectal Cancer · Elderly Patients

#ElderlyPatients#Antibody#Phase3#항체#면역항체+3

임상시험 1상태 RECRUITING

ADCBiologicstaleQilu Pharmaceutical Co., Ltd.Phase 2

QLS5133 (QLS5133)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

CGTBiologicstaleHadassah Medical OrganizationPhase 2

HBI 0201-ESO TCRT (HBI 0201-ESO TCRT)

Sarcoma, Synovial; Sarcoma,Soft Tissue · Sarcoma, Synovial

#SarcomaSynovial#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

AntibodystaleNovartis PharmaceuticalsPhase 3

Crizanlizumab (Crizanlizumab)

Sickle Cell Disease · Sickle Cell Disease

#SickleCellDisease#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleShanghai General Hospital, Shan…Phase 2

Cadonilimab+S-1or Capecitabine (Cadonilimab+S-1or Capecitabine)

Pancreatic Neoplasms · Pancreatic Neoplasms

#PancreaticNeoplasms#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

ADCBiologicstaleEli Lilly and CompanyPhase 1

LY4052031 (LY4052031)

Metastatic Solid Tumor; Recurrent Solid Tumor · Metastatic Solid Tumor

#MetastaticSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 RECRUITING

CGTBiologicstaleReplimune, Inc.Phase 2

RP1, intra-tumoral injection, oncolytic virus (RP1, intra-tumoral injection, oncolytic virus)

Merkel Cell Carcinoma; Basal Cell Carcinoma · Merkel Cell Carcinoma

#MerkelCellCarcinoma#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

AntibodystaleAbbViePhase 3

adalimumab (Humira, Adalimumab originator)

Plaque Psoriasis · Plaque Psoriasis

#PlaquePsoriasis#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleAbbViePhase 2

adalimumab (Humira, Adalimumab plus Methotrexate)

Uveitis · Uveitis

#Uveitis#Antibody#Phase2#항체#면역항체+2

효능 ORR 6.35%임상시험 1상태 ACTIVE

AntibodystaleNational Institute of Allergy a…Phase 1

VRC-HIVMAB0121-00-AB (VRC-HIVMAB0121-00-AB)

HIV Infection · HIV Infection

#HIVInfection#Antibody#Phase1#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleRocheApproved

tocilizumab [RoActemra/Actemra] (tocilizumab [RoActemra/Actemra])

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Approved#항체#면역항체+2

임상시험 1상태 DISCONTINUED

AntibodystaleSamsung Bioepis Co., Ltd.Approved

Adalimumab Biosimilar (SB5, SB5 (Adalimumab Biosimilar))

Plaque Psoriasis · Plaque Psoriasis

#PlaquePsoriasis#Antibody#Approved#항체#면역항체+2

효능 ORR 64%임상시험 1상태 ACTIVE

ADCBiologicstaleMythic TherapeuticsPhase 1

MYTX-011 (MYTX-011)

NSCLC; NSCLC Stage IV · NSCLC

#NSCLC#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 DISCONTINUED

CGTBiologicstaleThe Methodist Hospital Research…Phase 2

IL-12 gene therapy (IL-12 gene therapy)

Triple Negative Breast Cancer; Anthracycline-refractory TNBC · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+4

효능 ORR 90%임상시험 1상태 DISCONTINUED

ADCBiologicstaleXijing HospitalPhase 2

Neratinib Combined with Fulvestrant and Eribulin (Neratinib Combined with Fulvestrant and Eribulin)

Brest Cancer · Brest Cancer

#BrestCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

82 / 167 페이지

← 이전 다음 →

전체 9,268개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 0 / 738

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

Anti-Thyroglobulin mTCR PBL (Anti-Thyroglobulin mTCR PBL)

JSKN033 (JSKN033)

Observational Cohort (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (Observational Cohort))

autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes (autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes)

TQB2922 injection+TAS-102 tablets ± Bevacizumab (TQB2922 injection+TAS-102 tablets ± Bevacizumab)

ADP-TILIL7 (ADP-TILIL7)

EGFR inhibitors (panitumumab, panitumumab (EGFR inhibitors))

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan + FLO)

ENV-501 (ENV-501)

JS001+Bevacizumab (JS001+Bevacizumab)

Capecitabine plus bevacizumab (Capecitabine plus bevacizumab)

QLS5133 (QLS5133)

HBI 0201-ESO TCRT (HBI 0201-ESO TCRT)

Crizanlizumab (Crizanlizumab)

Cadonilimab+S-1or Capecitabine (Cadonilimab+S-1or Capecitabine)

LY4052031 (LY4052031)

RP1, intra-tumoral injection, oncolytic virus (RP1, intra-tumoral injection, oncolytic virus)

adalimumab (Humira, Adalimumab originator)

adalimumab (Humira, Adalimumab plus Methotrexate)

VRC-HIVMAB0121-00-AB (VRC-HIVMAB0121-00-AB)

tocilizumab [RoActemra/Actemra] (tocilizumab [RoActemra/Actemra])

Adalimumab Biosimilar (SB5, SB5 (Adalimumab Biosimilar))

MYTX-011 (MYTX-011)

IL-12 gene therapy (IL-12 gene therapy)

Neratinib Combined with Fulvestrant and Eribulin (Neratinib Combined with Fulvestrant and Eribulin)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

Anti-Thyroglobulin mTCR PBL (Anti-Thyroglobulin mTCR PBL)

JSKN033 (JSKN033)

Observational Cohort (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (Observational Cohort))

autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes (autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes)

TQB2922 injection+TAS-102 tablets ± Bevacizumab (TQB2922 injection+TAS-102 tablets ± Bevacizumab)

ADP-TILIL7 (ADP-TILIL7)

EGFR inhibitors (panitumumab, panitumumab (EGFR inhibitors))

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan + FLO)

ENV-501 (ENV-501)

JS001+Bevacizumab (JS001+Bevacizumab)

Capecitabine plus bevacizumab (Capecitabine plus bevacizumab)

QLS5133 (QLS5133)

HBI 0201-ESO TCRT (HBI 0201-ESO TCRT)

Crizanlizumab (Crizanlizumab)

Cadonilimab+S-1or Capecitabine (Cadonilimab+S-1or Capecitabine)

LY4052031 (LY4052031)

RP1, intra-tumoral injection, oncolytic virus (RP1, intra-tumoral injection, oncolytic virus)

adalimumab (Humira, Adalimumab originator)

adalimumab (Humira, Adalimumab plus Methotrexate)

VRC-HIVMAB0121-00-AB (VRC-HIVMAB0121-00-AB)

tocilizumab [RoActemra/Actemra] (tocilizumab [RoActemra/Actemra])

Adalimumab Biosimilar (SB5, SB5 (Adalimumab Biosimilar))

MYTX-011 (MYTX-011)

IL-12 gene therapy (IL-12 gene therapy)

Neratinib Combined with Fulvestrant and Eribulin (Neratinib Combined with Fulvestrant and Eribulin)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

Anti-Thyroglobulin mTCR PBL (Anti-Thyroglobulin mTCR PBL)

JSKN033 (JSKN033)

Observational Cohort (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (Observational Cohort))

autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes (autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes)

TQB2922 injection+TAS-102 tablets ± Bevacizumab (TQB2922 injection+TAS-102 tablets ± Bevacizumab)

ADP-TILIL7 (ADP-TILIL7)

EGFR inhibitors (panitumumab, panitumumab (EGFR inhibitors))

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan + FLO)

ENV-501 (ENV-501)

JS001+Bevacizumab (JS001+Bevacizumab)

Capecitabine plus bevacizumab (Capecitabine plus bevacizumab)

QLS5133 (QLS5133)

HBI 0201-ESO TCRT (HBI 0201-ESO TCRT)

Crizanlizumab (Crizanlizumab)

Cadonilimab+S-1or Capecitabine (Cadonilimab+S-1or Capecitabine)

LY4052031 (LY4052031)